Drugs / CodaLytic
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05600582 | Jan 2023 → Sep 2024 | breast cancer, metastatic malignant neoplasm | Codagenix, Inc | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-10-30 | Codagenix, Inc | Results Codagenix Announces Presentation of Updated Preclinical CodaLyticTM Data at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting codagenix.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-10-30 | Codagenix, Inc | Codagenix Announces Presentation of Updated Preclinical CodaLyticTM Data at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting codagenix.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CodaLytic | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05600582 ↗ |
| Modality | Other / unclassified | “CodaLytic is a virotherapeutic product based on the wild-type influenza strain A/California/07/2009” NCT05600582 ↗ |
| Route | Other | “administered intratumorally” NCT05600582 ↗ |